TABLE 1.
Subject demographics, serologies, and hybridoma yields from DENV-immune subjectsa
| Type of infection | Donor no. | Infecting serotype(s) | Location acquired | Yr of infection | Time since infection (yr) | Reciprocal serum Ab 50% neutralization titer to DENV serotype: |
No. of wells with DENV-reactive supernatants/total no. of wells tested | Estimated frequency of DENV-specific B cells in circulation (10−4) | No. of hybridomas obtained | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||||||||
| Secondary | 1 | 1 and 3 | Mexico | 2006 | 4 | 282 | 209 | 166 | 76 | 178/3,840 | 14 | 27 |
| Primary | 2 | 3 | Nicaragua | 2009 | 1 | 60 | 32 | 980 | 76 | 90/1,536 | 18 | 14 |
| 3 | 2 | Sri Lanka | 1996 | 9 | < | 271 | < | 42 | 117/2,304 | 16 | 9 | |
a
<, titer of <1:20. Live-DENV-reactive B cell frequencies were estimated using the number of wells with DENV-reactive supernatants divided by the total number of lymphoblastoid B cell colony counts in the transformation plate (i.e., the total number of B cells investigated).